SCHEMBL20096928

SCHEMBL20096928

Nc1ncnc2c1ncn2C1OC(CNCc2ccccn2)C(O)C1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.67
DOT1L Q8TEK3 3/20 0.66
ADORA1 P30542 3/20 0.61
DPP4 P27487 1/20 0.61
MEN1 O00255 1/20 0.61
SLC28A1 O00337 1/20 0.61
MAP3K7 O43318 1/20 0.61
SLC28A2 O43868 1/20 0.61
GAPDH P04406 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
MAPK1 P28482 1/20 0.61
ADORA2A P29274 1/20 0.61
ADORA2B P29275 1/20 0.61
STAT6 P42226 1/20 0.61
PI4KA P42356 1/20 0.61
KMT2A Q03164 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
PI4K2B Q8TCG2 1/20 0.61
SLC29A1 Q99808 1/20 0.61
PI4K2A Q9BTU6 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6908400 0.91 DOT1L (0.61) ATMDOT1LADORA1DPP4MEN1
SCHEMBL6900816 0.87 ATM (0.76) ATMDOT1LADORA1DPP4MEN1
SCHEMBL26668606 0.83 GNMT (0.72) ATMDOT1LADORA1DPP4MEN1
SCHEMBL6907677 0.81 DOT1L (0.71) DOT1LKMT2ANADKAHCYNNMT
SCHEMBL6901588 0.81 DOT1L (0.67) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL13986406 0.81 ADORA3 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL7062240 0.81 ADORA3 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL7062257 0.81 ADORA3 (0.73) DOT1LADORA1DPP4MEN1SLC28A1
SCHEMBL9053638 0.81 DOT1L (0.66) ATMDOT1LADORA1DPP4MEN1
SCHEMBL9053631 0.81 DOT1L (0.66) ATMDOT1LADORA1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 US disclosed
WO-2018075947-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 ATM 3776/4885DOT1L 2274/4885ADORA1 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.